Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
The present invention provides methods of increasing the half-life factor VIII. More specifically, the invention methods of increasing the half-life of factor VIII by substituting amino acids in the A2 domain or in the C2 domain of factor VIII or in both domains. It further provides factor VIII mutants produced by these methods. The invention also provides a method of using receptor-associated protein (RAP) to increase the half-life of factor VIII. The invention also provides polynucleotides encoding the mutant factor VIII, polynucleotides encoding RAP, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
1. A isolated polynucleotide encoding a mutant factor VIII polypeptide, wherein said mutant factor VIII polypeptide consists of a human or porcine factor VIII polypeptide containing at least one nonconservative amino acid substitution at a position corresponding to an amino acid selected from the group consisting of Lys (380), Lys (512), Lys (523), Lys (556), Lys (570), Arg (571), and Lys (659) of SEQ ID NO: 5, and wherein said mutant factor VIII polypeptide exhibits procoagulant activity and reduced heparan sulfate proteoglycan (HSPG)-dependent, receptor-independent clearance.
2. A isolated polynucleotide encoding a mutant factor VIII polypeptide, wherein said mutant factor VIII polypeptide consists of a human or porcine factor VIII polypeptide containing a nonconservative amino acid substitution at a position corresponding to the amino acid at position Arg (490) of SEQ ID NO: 5, and at least one nonconservative amino acid substitution at a position corresponding to an amino acid selected from the group consisting of Lys (380), Lys (512), Lys (523), Lys (556), Arg (562), Lys (570), Arg (571), and Lys (659) of SEQ ID NO: 5, and wherein said mutant factor VIII polypeptide exhibits procoagulant activity and reduced heparan sulfate proteoglycan (HSPG)-dependent, receptor-independent clearance.
3. A isolated polynucleotide encoding a mutant factor VIII polypeptide, wherein said mutant factor VIII polypeptide consists of a human or porcine factor VIII polypeptide containing two or more nonconservative amino acid substitutions at a position corresponding to an amino acid selected from the group consisting of Lys (380), Lys (512), Lys (523), Lys (556), Arg(562), Lys (570), Arg (571), and Lys (659) of SEQ ID NO: 5, and wherein said mutant factor VIII polypeptide exhibits procoagulant activity and reduced heparan sulfate proteoglycan (HSPG)-dependent, receptor-independent clearance.